It was better than Stelara in reaching ... impacting the lives of psoriasis patients,” he added. BE VIVID will follow patients for a year after starting treatment, so additional readouts will ...

Currently, all biologic treatments for psoriasis, including anti-tumour necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe.

Later this month, the US Food and Drug Administration (FDA) will decide whether a new psoriasis drug, Stelara (ustekinumab), can enter the market. The human monoclonal antibody (mAb), developed by ...

said Thursday it has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States. Steqeyma, a treatment for plaque psoriasis, Crohn's disease, active ...

Although the Stelara exclusivity is around the corner, Johnson & Johnson has "numerous new product cycles across multiple large markets such as IBD, psoriasis, neuropsych, multiple myeloma ...

demonstrating its equivalent efficacy to Janssen Pharmaceuticals' anti-psoriasis brand, Stelara. Stelara costs approximately ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition ...

STEQEYMA is approved for the same indications as STELARA, providing consistency in treatment for patients and healthcare providers.[1] "Chronic inflammatory diseases such as plaque psoriasis and ...